Compare Inovio Pharmaceuticals Inc (INO) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs VNET Group Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: VNET Group Inc is far larger — about 13.1× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and VNET Group Inc for 16 Days on average.
| INO | VNET | |
|---|---|---|
Market Cap | $112.19M | $1.47B |
Volume | 3,201,278 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $2.65 | $14.03 |
52-Week Low | $0.66 | $5.13 |
Typical Hold Time | 43 Days | 16 Days |
Enterprise Value | $83.51M | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
VNET trades at $5.17, down 4.08% today, near 52-week lows. The stock is technically bearish with weak moving averages. Fundamentally, revenue grew to $9.95B in 2025, but net losses persist with a -22.18% margin. Recent news includes a strategic investment closing and a cooperation agreement with CATL.
Outlook remains challenged by losses and high leverage, though analyst consensus is moderately bullish. Key risks include negative cash flow and execution uncertainty. The stock offers speculative appeal if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
